Emmes

Government Clinical Research Services

Committed to delivering fast, efficient, high-quality programs through the end-to-end use of technology & AI

Emmes is a full-service clinical research organization (CRO) dedicated to serving government, biopharmaceutical, non-profit, & academic partners in achieving their development & human health goals.

Founded nearly 50 years ago, we became one of the primary clinical research providers to the US government before expanding into publicprivate partnerships & commercial biopharma. Emmes has built industryleading capabilities in Vaccines & Infectious Diseases, Neuroscience, Ophthalmology, Cell & Gene Therapy & Rare Diseases in the following types of programs.

Statistical & Data Coordinating Centers (SDCCs)	Full Service Clinical Trials
Clinical Research Support Services (CRSS) Partnerships	Clinical Site Monitoring Centers (CSMCs)

Emmes spearheaded the industry's first truly unified electronic clinical platform technology, *Advantage eClinical Cloud*. The difficulty in dealing with numerous systems that do not sync well together led us to create a single application for patients, sites, CROs, & sponsors to conduct clinical research. The unified AI-driven platform delivers insights at scale from study start-up to filing, patient & site engagement, data management, biostatistics, & bioinformatics. Allowing the end user to put their focus back on the next generation of treatments.

Functional Area Expertise

- Digital & Decentralized Clinical Trials (DCTs)
- Biostatistics, Data Science, & Bioinformatics
- Clinical Data Management
- Clinical Site Management & Monitoring
- Study Design, Site Feasibility, & Protocol Development
- Pharmacovigilance & Medical Monitoring
- Global Regulatory Affairs
- Cloud Systems Design & Engineering

Key Statistics

1,000,000+
Enrolled Subjects

2,150+
Clinical Trials (CT) Completed

400+
Late-Stage CT in Public & Biopharma Sectors

32,000+
CT Sites Engaged Globally

75+
Countries Participating in Clinical Programs

450+
Manuscripts in Leading Peer- Reviewed Journals Since 2016

Advantage eClinical Cloud Unified Platform

- Global Trace- eSpecimen Tracking System
- eCOA/ePRO
- eConsent
- Telehealth Applications

FISMA COMPLIANCE | FR FedRAMP | FDA 21 CFR Part 11 COMPLIANCE | ATO

- Lab Data
- Sensor Data
- Imaging Data
- Instruments
- Omics Data
- Real World Data

APPLICATIONS

DCT eCOA, ePRO, eConsent

Global Trace · RTSM · RBCM · Study Builder · Clinical Pipelines · Reporting and Analytics · User Management · EDC

Advantage eClinical Cloud

PLATFORM COMPONENTS

One Unified Platform
Log in once to access and navigate across all applications

Single Database
Work with data across the platform without expensive messy integrations

Unified Study Build
Perform study builds in one place for all your applications

Streamlined Role Administration
Manage sites and users across all trials and applications

Active Government Partnerships
Partner with us on the next generation of clinical research

Vaccines & Infectious Diseases

650+ Vaccine & Infectious Disease Clinical Trials

NIAID | Division of Microbiology and Infectious Disease | Statistical Data Coordinating Center: Since 1996, we have supported more than 315+ domestic & international VID protocols as the SDCC for NIAID's DMID extramural program. More than 150 active clinical trials evaluating vaccines & treatment strategies for infectious pathogens, including COVID-19, Ebola, influenza, Zika, Chikungunya, e. coli, shigella, c. difficile, norovirus, & rotavirus, as well as emerging infectious diseases & bioterrorism threats.

NIAID | Division of Microbiology and Infectious Disease | Adaptive COVID-19 Treatment Trial (ACTT): Since 2020, Emmes has served as the Statistical and Data Coordinating Center (SDCC) for the NIAID-DMID-sponsored Adaptive COVID-19 Treatment Trials (ACTT), a series of pivotal licensure trials for COVID-19 therapeutics and part of Operation Warp Speed. Selected by the National Institutes of Health, Emmes has provided comprehensive statistical, data management, and project management support across all four phases of ACTT. These landmark trials supported two Emergency Use Authorizations (EUAs) and have significantly shaped global treatment guidelines. Findings from ACTT have been published in high-impact journals, advancing the clinical understanding of antiviral, anti-inflammatory, and immunomodulatory therapies for hospitalized COVID-19 patients.

NIAID | Collaborative Influenza Vaccine Innovation Centers (CIVICs): Since 2019, Emmes has supported the NIAID's Collaborative Influenza Vaccine Innovation Centers (CIVICs) program, a pioneering effort to develop broadly protective, longer-lasting influenza vaccines. As part of a multidisciplinary network of academic institutions, medical centers, and industry partners, Emmes provides data management and statistical support for preclinical and clinical research aimed at advancing next-generation and universal influenza vaccine strategies. This program builds on our long-standing experience supporting clinical trials for influenza and other emerging infectious diseases, including Zika and Ebola, and represents a critical step in transforming the future of flu prevention.

NIAID | Vaccine Research Center | Data Management, Warehousing, & Clinical Site Monitoring: Since 2001, we have been the clinical data management partner for more than 55 protocols for NIAID's VRC. Provide expert data management & data warehousing support for the development of new vaccines & mAb therapies for emerging infectious disease threats, including HIV, malaria, West Nile virus, Chikungunya virus, zika virus, Severe Acute Respiratory Syndrome (SARS), Ebola, Marburg, smallpox, RSV, & influenza (avian, seasonal, H1N1 & H5N1 pandemic influenza virus & universal influenza vaccine strategies).

NIAID | Vaccine Intramural Research Center | Comprehensive and Rapid Response for NIAID Research Programs (CARRRP): Since 2022, Emmes has supported NIAID's Vaccine Intramural Research Center through the Comprehensive and Rapid Response for NIAID Research Programs (CARRRP) initiative. This program enables a flexible, accelerated response to urgent and emerging public health threats. As a key partner, Emmes provides data management, statistical, and project coordination expertise to advance high-priority vaccine and therapeutic research. Through CARRRP, we help facilitate rapid study start-up, robust data systems, and high-quality analyses to support NIAID's mission in pandemic preparedness and infectious disease response.

NIAID / Leidos Biomedical Research | NEXT GEN and H5N1 programs: Emmes supports the NIAID and Leidos Biomedical Research through the NEXT GEN and H5N1 programs, advancing the development of next-generation and pandemic influenza vaccines. Our team provides expert data management, tatistical, and project support for clinical research aimed at evaluating novel vaccine platforms and countermeasures against high-risk influenza strains, including H5N1. This work plays a key role in strengthening pandemic preparedness and accelerating vaccine innovation for global public health threats

---

NAICS CODES | 541714 | 541715 | 5415XX | 5416XX | 541720 | 541990   **BUSINESS SIZE | LARGE | UEI | NBQCBJ6FXBU4**

Emmes